Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration

Journal Article · Thu Jan 14 23:00:00 EST 2021 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2020.08.055· OSTI ID:23198712

Hoppe, Bradford S. ^[1]; Dedeckova, Katerina ^[2]; Patel, Chirayu G. ^[3]; Hill-Kayser, Christine E. ^[4]; others, and

---

1. Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville (United States)
2. Proton Therapy Center Czech (Czech Republic)
3. Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA (United States)
4. Department of Radiation Oncology, Perelman School of Medicine of the University of Pennsylvania, Philadelphia (United States)

Despite high response rates, there has been reluctance to use radiation therapy for patients with relapsed/refractory (r/r) Hodgkin (HL) or aggressive non-Hodgkin lymphoma (NHL) given concerns for subacute and late toxicities. Symptomatic pneumonitis, a subacute toxicity, has an incidence of 17% to 24% (≥grade 2) even with intensity modulated radiation therapy. Proton therapy (PT), which has no exit radiation dose, is associated with a lower dose to lung compared with other radiation techniques. As risk of radiation pneumonitis is associated with lung dose, we evaluated whether pneumonitis rates are lower with PT.

• OSTI ID: 23198712
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 1 Vol. 109; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
HEALTH HAZARDS
LUNGS
LYMPHOMAS
PATIENTS
PNEUMONITIS
PROTON BEAMS
RADIATION DOSES
RADIOTHERAPY
TOXICITY